Aaron Holtebeck, MD
Ophthalmology · Brookfield, WINPI 1760400147
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Sight Sciences, Inc. at 53.8% of the total. Reporting peaked in 2019 at $4,898 and has fallen 74.2% since, to $1,264 in 2025. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $56.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$8K
- Alcon$2K
- AbbVie$2K
- Amgen$385
- Regeneron Healthcare Solutions, Inc.$303
- Apellis Pharmaceuticals, Inc.$171
- plus $1K from 21 others
What the payments were for
- Consulting fees$7,10048%
- Speaking & faculty fees$5003%
- Travel & lodging$120%
- Food & beverage$6,89147%
- Education$1121%
- Other$1741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 39 | $7,963 |
| Alcon | 85 | $2,415 |
| AbbVie(2 entities) | 43 | $2,365 |
| Amgen(2 entities) | 16 | $385 |
| Regeneron Healthcare Solutions, Inc. | 9 | $303 |
| Apellis Pharmaceuticals, Inc. | 9 | $171 |
| Astellas Pharma US Inc | 4 | $126 |
| Glaukos Corporation | 5 | $118 |
| Mallinckrodt Hospital Products Inc. | 6 | $115 |
| Rayner Intraocular Lenses Limited | 5 | $107 |
| NEW World Medical,inc. | 7 | $97 |
| Oyster Point Pharma, Inc. | 4 | $79 |
| Novartis | 4 | $79 |
| Rxsight Inc | 2 | $65 |
| Biotissue Holdings Inc. | 3 | $49 |
| Genentech USA, Inc. | 3 | $48 |
| Tarsus Pharmaceuticals, Inc. | 2 | $45 |
| Dompe US, Inc. | 2 | $39 |
| Thea Pharma Inc. | 2 | $38 |
| Ocular Therapeutix, Inc. | 2 | $33 |
| Harrow Eye, LLC | 1 | $29 |
| LKC Technologies, Inc. | 1 | $29 |
| Bausch & Lomb Americas Inc. | 2 | $26 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $26 |
| Lumibird Medical Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Omeros Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI$6,608
- DURYSTA$1,100
- OMNI(R) SURGICAL SYSTEM (US)$606
- SION SURGICAL INSTRUMENT$242
- XEN GLAUCOMA TREATMENT SYSTEM$225
- AcrySof IQ PanOptix UV IOL$151
- EYLEA$133
- Luxor$132
- AcrySof IQ PanOptix$125
- Centurion$125
- Clareon$107
How this compares
$14,789 in reported general payments places this provider in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $32,626 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $2,909 |
| ErythromycinErythromycin Base | 257 | $2,887 |
| Latanoprost | 228 | $2,273 |
| Brinzolamide | 14 | $1,811 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 126 | $1,568 |
| Prednisolone Acetate | 22 | $1,122 |
| Timolol Maleate | 60 | $571 |
| Brimonidine Tartrate | 35 | $472 |
| Ofloxacin | 24 | $277 |
| Dorzolamide Hcl | 14 | $171 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $2,365 | $32,62639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Brookfield
- Kathy HwangBrookfield$3K
- Ivan IrelandBrookfield$2K
- Inder SinghRacine$2.5M
- Deepak SambharaWausau$388K
- John VukichWauwatosa$356K
- Eugene EldridgeKenosha$294K
- Michael ShapiroMadison$71K
- Douglas SalmAppleton$38K
- Julia AgapovMadison$26K
- Thomas HarveyChippewa Falls$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.